Home >> Ophthalmology >> Ophthalmology >> Baked Goods >> Technology & Media >>

Allergic Conjunctivitis - Pipeline Review, H1 2015

Published: Apr-2015 | Format: PDF | Global Markets Direct | Number of pages: 71 | Code: MRS - 18279

Allergic Conjunctivitis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Allergic Conjunctivitis - Pipeline Review, H1 2015’, provides an overview of the Allergic Conjunctivitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Allergic Conjunctivitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Conjunctivitis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Allergic Conjunctivitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Allergic Conjunctivitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Allergic Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Allergic Conjunctivitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Allergic Conjunctivitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Allergic Conjunctivitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Allergic Conjunctivitis Overview 8
Therapeutics Development 9
Pipeline Products for Allergic Conjunctivitis - Overview 9
Pipeline Products for Allergic Conjunctivitis - Comparative Analysis 10
Allergic Conjunctivitis - Therapeutics under Development by Companies 11
Allergic Conjunctivitis - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Allergic Conjunctivitis - Products under Development by Companies 15
Allergic Conjunctivitis - Companies Involved in Therapeutics Development 16
Alcon, Inc. 16
Allergan, Inc. 17
Celsus Therapeutics Plc 18
Eleven Biotherapeutics Inc. 19
Griffin Discoveries BV 20
Laila Pharmaceuticals Pvt. Ltd. 21
NicOx S.A. 22
Ocular Therapeutix, Inc. 23
Ohr Pharmaceutical Inc. 24
Oxagen Limited 25
Sun Pharma Advanced Research Company Ltd. 26
Xencor, Inc. 27
Allergic Conjunctivitis - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
AGN-229666 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
AL-53817 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
cetirizine hydrochloride - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
dexamethasone acetate SR - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Drugs for Allergic Conjunctivitis - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
GD-134 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
isunakinra - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
KBP-7306 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
LP-00209 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
OC-2417 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
OC-459 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
OPX-1 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Small Molecules to Antagonize Histamine H1/H4 Receptor for Ophthalmology and Asthma - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
SUN-0597 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
XmAb-7195 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Allergic Conjunctivitis - Recent Pipeline Updates 55
Allergic Conjunctivitis - Dormant Projects 64
Allergic Conjunctivitis - Discontinued Products 66
Allergic Conjunctivitis - Product Development Milestones 67
Featured News & Press Releases 67
Apr 16, 2015: Eleven Biotherapeutics Presents Phase 2 Clinical Data on EBI-005 for the Treatment of Allergic Conjunctivitis at ASCRS 2015 Annual Meeting 67
Jan 26, 2015: Nicox holds successful pre-NDA meeting with FDA on AC-170 clinical package 67
Oct 08, 2014: Aciex Therapeutics Announces Issuance of Separate U.S. Patents Covering AC-170 Product Candidate 68
Mar 04, 2014: Eleven Biotherapeutics Reports Clinical and Regulatory Updates for EBI-005 68
Apr 17, 2013: Celsus Therapeutics Receives US Patent Covering Product Candidate OPX-1 For Treatment Of Conjunctivitis 69
Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 70
Disclaimer 71

List of Tables
Number of Products under Development for Allergic Conjunctivitis, H1 2015 9
Number of Products under Development for Allergic Conjunctivitis - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Allergic Conjunctivitis - Pipeline by Alcon, Inc., H1 2015 16
Allergic Conjunctivitis - Pipeline by Allergan, Inc., H1 2015 17
Allergic Conjunctivitis - Pipeline by Celsus Therapeutics Plc, H1 2015 18
Allergic Conjunctivitis - Pipeline by Eleven Biotherapeutics Inc., H1 2015 19
Allergic Conjunctivitis - Pipeline by Griffin Discoveries BV, H1 2015 20
Allergic Conjunctivitis - Pipeline by Laila Pharmaceuticals Pvt. Ltd., H1 2015 21
Allergic Conjunctivitis - Pipeline by NicOx S.A., H1 2015 22
Allergic Conjunctivitis - Pipeline by Ocular Therapeutix, Inc., H1 2015 23
Allergic Conjunctivitis - Pipeline by Ohr Pharmaceutical Inc., H1 2015 24
Allergic Conjunctivitis - Pipeline by Oxagen Limited, H1 2015 25
Allergic Conjunctivitis - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2015 26
Allergic Conjunctivitis - Pipeline by Xencor, Inc., H1 2015 27
Assessment by Monotherapy Products, H1 2015 28
Number of Products by Stage and Target, H1 2015 30
Number of Products by Stage and Mechanism of Action, H1 2015 32
Number of Products by Stage and Route of Administration, H1 2015 34
Number of Products by Stage and Molecule Type, H1 2015 36
Allergic Conjunctivitis Therapeutics - Recent Pipeline Updates, H1 2015 55
Allergic Conjunctivitis - Dormant Projects, H1 2015 64
Allergic Conjunctivitis - Dormant Projects (Contd..1), H1 2015 65
Allergic Conjunctivitis - Discontinued Products, H1 2015 66

List of Figures
Number of Products under Development for Allergic Conjunctivitis, H1 2015 9
Number of Products under Development for Allergic Conjunctivitis - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Products, H1 2015 14
Assessment by Monotherapy Products, H1 2015 28
Number of Products by Top 10 Targets, H1 2015 29
Number of Products by Stage and Top 10 Targets, H1 2015 30
Number of Products by Top 10 Mechanism of Actions, H1 2015 31
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 32
Number of Products by Top 10 Routes of Administration, H1 2015 33
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 34
Number of Products by Top 10 Molecule Types, H1 2015 35
Number of Products by Stage and Top 10 Molecule Types, H1 2015 36

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing